Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

被引:471
作者
Trapp, Bruce D. [1 ]
Stys, Peter K. [2 ]
机构
[1] Lerner Res Inst, Cleveland Clin, Dept Neurosci NC30, Cleveland, OH 44195 USA
[2] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada
关键词
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MAGNETIC-RESONANCE-SPECTROSCOPY; CORD WHITE-MATTER; ADAPTIVE FUNCTIONAL-CHANGES; NITRIC-OXIDE; NMDA RECEPTORS; NEUROLOGICAL DISABILITY; GLUTAMATE RECEPTORS; MYELINATED AXONS; SODIUM-CHANNELS;
D O I
10.1016/S1474-4422(09)70043-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS), an inflammatory demyelinating disease, is a major cause of neurological disability in young adults in the developed world. Although the progressive neurological disability that most patients with MS eventually experience results from axonal degeneration, little is known about the mechanisms of axonal injury in MS. Accumulating evidence suggests that the increased energy demand of impulse conduction along excitable demyelinated axons and reduced axonal ATP production induce a chronic state of virtual hypoxia in chronically demyelinated axons. In response to such a state, key alterations that contribute to chronic necrosis of axons might include mitochondrial dysfunction (due to defective oxidative phosphorylation or nitric oxide production), Na+ influx through voltage-gated Na+ channels and axonal AMPA receptors, release of toxic Ca2+ from the axoplasmic reticulum, overactivation of ionotropic and metabotropic axonal glutamate receptors, and activation of voltage-gated Ca2+ channels, ultimately leading to excessive stimulation of Ca2+-dependent degradative pathways. The development of neuroprotective therapies that target these mechanisms might constitute effective adjuncts to currently used immune-modifying agents.
引用
收藏
页码:280 / 291
页数:12
相关论文
共 109 条
  • [1] Agrawal SK, 1997, J NEUROSCI, V17, P1055
  • [2] ANTEL JP, 2004, MYELIN BIOL DISORDER, P791
  • [3] USE OF PROTON MAGNETIC-RESONANCE SPECTROSCOPY FOR MONITORING DISEASE PROGRESSION IN MULTIPLE-SCLEROSIS
    ARNOLD, DL
    RIESS, GT
    MATTHEWS, PM
    FRANCIS, GS
    COLLINS, DL
    WOLFSON, C
    ANTEL, JP
    [J]. ANNALS OF NEUROLOGY, 1994, 36 (01) : 76 - 82
  • [4] Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy
    Bartt, Russell E.
    [J]. CURRENT OPINION IN NEUROLOGY, 2006, 19 (04) : 341 - 349
  • [5] Sodium-mediated axonal degeneration in inflammatory demyelinating disease
    Bechtold, DA
    Smith, KJ
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 233 (1-2) : 27 - 35
  • [6] Axonal protection using flecainide in experimental autoimmune encephalomyelitis
    Bechtold, DA
    Kapoor, R
    Smith, KJ
    [J]. ANNALS OF NEUROLOGY, 2004, 55 (05) : 607 - 616
  • [7] Axonal protection achieved in a model of multiple sclerosis using lamotrigine
    Bechtold, David A.
    Miller, Sandra J.
    Dawson, Angela C.
    Sun, Yue
    Kapoor, Raju
    Berry, David
    Smith, Kenneth J.
    [J]. JOURNAL OF NEUROLOGY, 2006, 253 (12) : 1542 - 1551
  • [8] Acute axonal injury in multiple sclerosis -: Correlation with demyelination and inflammation
    Bitsch, A
    Schuchardt, J
    Bunkowski, S
    Kuhlmann, T
    Brück, W
    [J]. BRAIN, 2000, 123 : 1174 - 1183
  • [9] Bjartmar C, 2000, ANN NEUROL, V48, P893, DOI 10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.3.CO
  • [10] 2-2